Neuropace (NPCE) vs Senseonics (SENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neuropace (NPCE) has outperformed Senseonics (SENS) over the past year, gaining 11.3% versus a loss of 2.3%. Over five years, NPCE leads with a -18.6% price change compared with -86.1% for SENS. Senseonics is the larger company by market cap ($476.9 million vs $425.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NPCE | SENS |
|---|---|---|
| Share price | $12.39 | $9.02 |
| Market cap | $425.28M | $476.92M |
| 1-day change | -2.90% | -1.53% |
| YTD return | -19.75% | +65.94% |
| 1-year return | +11.32% | -2.35% |
| 5-year return | -18.57% | -86.12% |
| EPS (TTM) | $-0.57 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.60 | $10.64 |
| 52-week low | $9.22 | $4.79 |
| Distance from 52-week high | -36.79% | -15.23% |
| Analyst consensus | none | buy |
| Avg. price target upside | +61.42% | +49.67% |
| Average volume | 169.86K | 675.36K |
| Shares outstanding | 34.32M | 52.87M |
| Employees | 220 | 130 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NPCE has outperformed SENS by 13.7 percentage points over the past year.
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 220 employees
About Senseonics
SENS stock →Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Health Care · Medical/Dental Instruments · 130 employees
NPCE vs SENS FAQ
Which is bigger, Neuropace or Senseonics?
Senseonics (SENS) is larger, with a market capitalization of $476.92M compared with $425.28M for Neuropace (NPCE).
Which stock has performed better over the past year, NPCE or SENS?
NPCE returned +11.32% over the past 12 months, compared with -2.35% for SENS (price return, excluding dividends). Past performance does not predict future results.
Are Neuropace and Senseonics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.